In-hospital outcomes of anemic patients with acute coronary syndrome receiving ticagrelor versus clopidogrel: Results of the Chinese Cardiovascular Care Improvement (CCC)-Acute Coronary Syndrome Project  

作　　者：Zhiqiang Zhang Yasong Wang Jun Wang Xiaofan Cao Miaohan Qiu Xiaoxiang Tian Yaling Han Xiaozeng Wang 

机构地区：[1]National Key Laboratory of Frigid Zone Cardiovascular Disease,Cardiovascular Research Institute and Department of Cardiology,General Hospital of Northern Theater Command,Shenyang,Liaoning 110016,China [2]The General Hospital of Northern Theater Command Training Base for Graduate,China Medical University,Shenyang,Liaoning 110016,China.

出　　处：《Chinese Medical Journal》2024年第20期2489-2491,共3页中华医学杂志(英文版)

基　　金：This study was supported by the China National Key R&D Project (contract No. 2022YFC2503500);The CCC-ACS project is a program of the AHA and the CSC. The AHA received funding from Pfizer through an independent grant for learning and change and Astra-Zeneca as a quality improvement initiative.

摘　　要：To the Editor:Dual antiplatelet therapy(DAPT),which comprises aspirin plus a P2Y12 receptor inhibitor,is the standard approach for reducing cardiac and systemic ischemic events in individuals with coronary artery disease.[1]Although DAPT reduces ischemic episodes,it also increases the risk of bleeding.In individuals with acute coronary syndrome(ACS),bleeding incidents during hospitalization not only greatly increase the risk of in-hospital death but also increase the risk of long-term mortality and major adverse cardiovascular events.[2]Therefore,the management of DAPT must consider both bleeding and ischemic risks.Anemia is a frequently observed complication in individuals diagnosed with ACS.[3]Anemic patients have increased susceptibility to ischemia and bleeding events after percutaneous coronary intervention(PCI),especially in the case of ACS.[4]There are presently no particular guidelines for early antiplatelet treatment in anemic individuals with ACS receiving PCI.Therefore,the aim of our study was to assess the in-hospital effectiveness and safety of ticagrelor and clopidogrel in anemic ACS patients undergoing PCI.

关 键 词：coronary PATIENTS BLEEDING 

分 类 号：R54[医药卫生—心血管疾病]